TENX
Tenax Therapeutics Inc
NASDAQ: TENX · HEALTHCARE · BIOTECHNOLOGY
$1.86
-4.62% today
Updated 2026-09-11
Market cap
$72.60M
P/E ratio
—
P/S ratio
414.72x
EPS (TTM)
$-1.48
Dividend yield
—
52W range
$1 – $19
Volume
6.2M
WallStSmart proprietary scores
40
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C5.5
Quality
C+3.0
Profitability
D5.3
Valuation
C+1/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$12.56
+575.27%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy5 Buy4 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-14.15M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-11.05M | $-7.71M | $-17.60M | $-52.60M | $-17.80M |
| EPS | — | — | — | — | $-1.48 |
| Free cash flow | $-12.02M | $-5.91M | $-14.81M | $-35.80M | $-14.15M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-13 | GIORDANO, CHRISTOPHER THOMAS | Sale | 8,500 | — |
| 2026-07-13 | GIORDANO, CHRISTOPHER THOMAS | Sale | 219 | — |
| 2026-07-13 | GIORDANO, CHRISTOPHER THOMAS | Buy | 8,500 | $5.94 |
Peer comparison
Smart narrative
Tenax Therapeutics Inc trades at $1.86. Our Smart Value Score of 40/100 indicates the stock is fair. The company scores 1/9 on the Piotroski F-Score.
Frequently asked questions
What is Tenax Therapeutics Inc's stock price?
Tenax Therapeutics Inc (TENX) trades at $1.86, on a P/S of 414.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Tenax Therapeutics Inc overvalued?
Tenax Therapeutics Inc carries a Smart Value Score of 40/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Tenax Therapeutics Inc (TENX)?
The 12-month analyst consensus target is $12.56, about 575.3% above the current $1.86. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio414.72x
ROE-50.49%
Beta0.82
50D MA$9.82
200D MA$11.89
Shares out0.04B
Float0.03B
Short ratio—
Avg volume6.2M
Performance
1 week-90.05%
1 month-92.17%
3 months-88.70%
YTD-88.72%
1 year—
3 years—
5 years—